Journal
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
Volume 47, Issue 1, Pages 705-714Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/21691401.2019.1573175
Keywords
Human serum albumin; liposomes; calcein; breast cancer; ultrasound
Categories
Funding
- American University of Sharjah Faculty Research Grants
- Al-Jalila Foundation [AJF 2015555]
- Al Qasimi Foundation
- Patient's Friends Committee-Sharjah
- Dana Gas Endowed Chair for Chemical Engineering
Ask authors/readers for more resources
Targeted liposomes have high potentials in the specific and effective delivery of their loaded therapeutic agents to the tumour site. Once at the tumour site, it is important that these liposomes are triggered to release their load in a controlled and effective manner. In this study, pegylated (stealth) liposomes conjugated to human serum albumin (HSA) were investigated for the delivery of a model drug (calcein) to breast cancer cells. The fluorescent results showed that calcein uptake by the two breast cancer cell lines (MDA-MB-231 and MCF-7) was significantly higher with the HSA-PEG liposomes compared to the non-targeted control liposomes. Furthermore, the exposure to low-frequency ultrasound (LFUS) resulted in a statistically significant uptake of calcein compared to the uptake without ultrasound. The described drug delivery (DD) system, which involves combining the targeted liposomal formulation with ultrasonic triggering techniques, promises a safe, effective and site-specific breast cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available